MCM
TEVA icon

Marathon Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Marathon Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-21,000
Closed -$205K – 217
2021
Q3 		$205K Hold
21,000
– – 0.05% 210
2021
Q2 		$207K Sell
21,000
-2,500
-11% -$26.5K 0.05% 187
2021
Q1 		$271K Hold
23,500
– – 0.07% 143
2020
Q4 		$226K Buy
23,500
+1,000
+4% +$9.58K 0.07% 139
2020
Q3 		$202K Sell
22,500
-3,275
-13% -$34.6K 0.07% 134
2020
Q2 		$277K Buy
+25,775
New +$292K 0.11% 96

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Marathon Capital Management's TEVA Position: Q4 2021 in Review

Marathon Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2021, closing a stake of 21,000 shares — an estimated $205K sold.

Marathon Capital Management first reported a position in TEVA in Q2 2020 and held it in 6 quarters. The position peaked at $277K in Q2 2020. 450 funds tracked by Wall St. Rank hold TEVA as of Q4 2021.

  • Marathon Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Marathon Capital Management sold 21,000 Teva Pharmaceuticals shares in Q4 2021, an estimated $205K.
  • Marathon Capital Management first reported a position in Teva Pharmaceuticals in Q2 2020 and held it in 6 quarters.
  • Marathon Capital Management's Teva Pharmaceuticals position peaked at $277K in Q2 2020.
  • 450 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2021.

Based on Marathon Capital Management's 13F filing for Q4 2021, filed 9 Feb 2022.